Phase III Study of KX-826 With Adult Male Patients With AGA

Conditions: Androgenetic Alopecia Interventions: Drug: KX-826- （5%） BID; Other: Placebo Sponsors: Suzhou Kintor Pharmaceutical Inc,; Suzhou Koshine Biomedica, Inc. Active, not recruiting

https://clinicaltrials.gov/study/NCT06126965

Source: ClinicalTrials.gov - November 10, 2023 Category: Research Source Type: clinical trials

More News: Alopecia | Research | Study